CRP

U.S. Minority Business Development Agency & Port of Seattle Announce New Collaboration to Expand Minority Business

Retrieved on: 
星期三, 五月 22, 2024
Partnership, Aviation, CRP, Airport, Puget Sound, Growth, MBDA, Pacific Northwest, Enterprise software, Commerce, MOU, Creative industries

SEATTLE, May 22, 2024 (GLOBE NEWSWIRE) -- On Thursday, May 16th, Acting Under Secretary of Commerce for Minority Business Development Eric Morrissette traveled to Seattle to sign a Memorandum of Understanding (MOU) between the Minority Business Development Agency (MBDA) and the Port of Seattle.

Key Points: 
  • SEATTLE, May 22, 2024 (GLOBE NEWSWIRE) -- On Thursday, May 16th, Acting Under Secretary of Commerce for Minority Business Development Eric Morrissette traveled to Seattle to sign a Memorandum of Understanding (MOU) between the Minority Business Development Agency (MBDA) and the Port of Seattle.
  • “We look forward to working closely with the Port of Seattle to identify aviation and port industry opportunities, support outreach efforts, and leverage our business center network” said Acting Under Secretary of Commerce for Minority Business Development Eric Morrissette.
  • Through this initiative, they offer training and development to help companies seeking to do business with the Port about diversity in contracting.
  • “This MOU is a huge milestone for the Port of Seattle and the Minority Business Development Agency under the auspices of the U.S. Department of Commerce.

Beckman Coulter and MeMed Extend Partnership Advancing Host Immune Response Diagnostics

Retrieved on: 
星期二, 五月 7, 2024
Ambiguity, BV, Genetically modified bacteria, TRAIL, Risk, Infection, Procalcitonin, Sepsis, CRP, Septic shock, Partnership, Research, NPV, PCT, Patient, Microbiology, Physician, Ministry, Serum, MDW, Beckman Coulter, CBC, Risk assessment, Viral, US FDA, Vaccine

BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed BV® assay, a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key®, a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe. This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers.

Key Points: 
  • BREA, Calif. and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, today announced expansion of their host immune response diagnostics partnership.
  • Beckman Coulter is now an authorized distributor of the MeMed BV® assay , a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key® , a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe.
  • This new distribution agreement complements the existing joint effort to develop a MeMed BV-based test for Beckman Coulter's family of Access Immunoassay Analyzers .
  • "To that end, we are excited to extend our partnership with MeMed by expanding market access to the MeMed Key and BV assay.

The Lundquist Institute Receives $2.6 Million Grant from U.S. Army Medical Research Acquisition Activity to Develop Wearable Biosensors

Retrieved on: 
星期四, 四月 25, 2024
UCLA, Mortality, Patient, Lower respiratory tract infection, Blood, Health, CRP, Death, Partnership, Doctor of Philosophy, Research, COPD, TLI, Electronics, Conditional sentence, AECOPD, Hospital, Perspiration, Infection, Disease, Chronic obstructive pulmonary disease, Pharmaceutical industry

Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.

Key Points: 
  • Torrance, California, April 24, 2024 (GLOBE NEWSWIRE) -- The U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded The Lundquist Institute (TLI) a four-year grant totaling $2,623,234.
  • The research project is led by Dr. Harry Rossiter, an investigator at TLI and Professor at the David Geffen School of Medicine at UCLA.
  • The project aims to develop wearable multiplex biosensors to monitor exacerbation risk in chronic obstructive pulmonary disease (COPD).
  • COPD affects approximately 16 million Americans and is the third leading cause of death globally.

The legendary luxury brokerage of Dallas, Fort Worth and North Texas brings on top relocation pro Janna Edgar as director of relocations and referrals; bar raised once again

Retrieved on: 
星期一, 四月 22, 2024
International, Museum, Sotheby's International Realty, Certification, CRP, Worldwide ERC, Pilates, Library, Consultant, Culture, Professional, Multimedia, Walking

DALLAS, April 22, 2024 /PRNewswire/ -- The leading luxury brokerage in Dallas and Fort Worth, Briggs Freeman Sotheby's International Realty, has appointed industry leader Janna Edgar, CRP, as its Director of Global Relocation and Referral Services.

Key Points: 
  • DALLAS, April 22, 2024 /PRNewswire/ -- The leading luxury brokerage in Dallas and Fort Worth, Briggs Freeman Sotheby's International Realty, has appointed industry leader Janna Edgar, CRP, as its Director of Global Relocation and Referral Services.
  • Edgar brings 20-plus years of experience and success in relocation services and strategies to the vital role.
  • At Briggs Freeman Sotheby's International Realty, the award-winning brokerage founded in Dallas in 1960 and specializing in fine homes, high-rises, ranches and land, Edgar will lead the firm's relocation, referral and lead-management initiatives.
  • Her responsibilities included overseeing all real estate programs for Odyssey's clients, with a focus on risk mitigation and program compliance.

Clinical Data Supports Novel Continuous Calprotectin Monitoring Wearable for IBD Management by EnLiSense

Retrieved on: 
星期一, 四月 8, 2024
Technology, Medical Devices, Health Technology, Nanotechnology, Other Health, Biotechnology, Hardware, Managed Care, Health, Data Management, Moses Austin, Conditional sentence, University, Professor, IL-6, Perspiration, Patient, Inflammation, Biomarker, Research, AI, Doctor of Philosophy, Senior, IBD, Translation, Management, C-reactive protein, Inflammatory bowel disease, Inflammatory Bowel Diseases, Trial of the century, CRP, Pharmaceutical industry

The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.

Key Points: 
  • The study showcases the IBD Aware device's ability to non-invasively monitor calprotectin levels in both active and remission phases of IBD.
  • These results not only affirm the accuracy of the IBD Aware device, but demonstrate its utility in the shifting paradigm of proactive IBD management that emphasizes continuous, data-driven decision-making.
  • “The IBD Aware device exemplifies our dedication to empowering healthcare professionals and enhancing patient outcomes through remote and continuous monitoring."
  • EnLiSense is pioneering work to build a future where proactive, personalized, and precision remote patient monitoring becomes the standard in chronic disease management.

Zone & Co Strengthens Leadership Team with Two Key Executive Appointments to Drive the Next Stage of Growth

Retrieved on: 
星期三, 四月 3, 2024
Cloud, GTM, Venture round, HR, AP, Garret, Organization, Growth, CFO, Payroll, ERP, History, Acquisition, IPO, TSX, Treasury, CAC, Vista Equity Partners, LTV, CRP, Rubicon Technologies, Renewable energy

Wonderling joins Zone with a history of leadership roles at pre- and post-IPO high-growth companies, most recently from Salesloft where he served as its Chief Accounting Officer.

Key Points: 
  • Wonderling joins Zone with a history of leadership roles at pre- and post-IPO high-growth companies, most recently from Salesloft where he served as its Chief Accounting Officer.
  • Garrett is an award-winning technology-marketing leader, who brings deep experience building out and leading revenue-driving global marketing organizations for both high-growth scale-ups and enterprise-level brands.
  • "Our company's trajectory is unmistakable, and I am eager to leverage our unique value proposition to captivate audiences and drive dominating growth.
  • We've only scratched the surface of its market potential and I look forward to helping unlock marketing-led growth."

Zone & Co Strengthens Leadership Team with Two Key Executive Appointments to Drive the Next Stage of Growth

Retrieved on: 
星期三, 四月 3, 2024
Cloud, GTM, Venture round, HR, AP, Garret, Organization, Growth, CFO, Payroll, ERP, History, Acquisition, IPO, TSX, Treasury, CAC, Vista Equity Partners, LTV, CRP, Rubicon Technologies, Renewable energy

Wonderling joins Zone with a history of leadership roles at pre- and post-IPO high-growth companies, most recently from Salesloft where he served as its Chief Accounting Officer.

Key Points: 
  • Wonderling joins Zone with a history of leadership roles at pre- and post-IPO high-growth companies, most recently from Salesloft where he served as its Chief Accounting Officer.
  • Garrett is an award-winning technology-marketing leader, who brings deep experience building out and leading revenue-driving global marketing organizations for both high-growth scale-ups and enterprise-level brands.
  • "Our company's trajectory is unmistakable, and I am eager to leverage our unique value proposition to captivate audiences and drive dominating growth.
  • We've only scratched the surface of its market potential and I look forward to helping unlock marketing-led growth."

ACORD's 2023 Annual Member Report Details Achievements in Industry-Wide Digitalization Efforts

Retrieved on: 
星期三, 三月 20, 2024
Organization, TSR, Transcriber, Reference architecture, Digital, CDR, Business, Total shareholder return, NGDS, Information model, Insurance, ADEPT, Architecture, LIP, Ecosystem, Metropolitan Cattle Market, Standard, Data, Representational state transfer, Risk, CRP

NEW YORK, March 20, 2024 /PRNewswire/ -- ACORD, the standards-setting body for the global insurance industry, today released its 2023 Member Report, detailing its efforts on behalf of its members over the past year. ACORD welcomed more than 100 new members across various stakeholder types, from carriers to brokers to solution providers. The report notes several key achievements, including:

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- ACORD, the standards-setting body for the global insurance industry, today released its 2023 Member Report, detailing its efforts on behalf of its members over the past year.
  • "ACORD is in a unique position to help shape the future of insurance," said Bill Pieroni, President & CEO of ACORD, in his annual message to the ACORD member community.
  • "We have witnessed great change in the industry, and ACORD has grown and changed alongside our members.
  • From the first standardized forms to AI-based solutions, ACORD has worked with our members to enable transformation and drive impact across our ecosystem."

Summary of opinion: Bimzelx, 21/03/2024 Positive

Retrieved on: 
星期三, 四月 3, 2024
Civil service commission, Psoriatic arthritis, Hidradenitis suppurativa, Methotrexate, Psoriasis, MRI, Magnetic resonance imaging, Inflammation, Committee, Nonsteroidal anti-inflammatory drug, Disease-modifying antirheumatic drug, HS, Medication package insert, C-reactive protein, Ankylosing spondylitis, European Commission, Marketing, CHMP, CRP, Axial spondyloarthritis

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bimzelx.

Key Points: 
  • On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Bimzelx.
  • The marketing authorisation holder for this medicinal product is UCB Pharma S.A.
  • The CHMP adopted a new indication for the treatment of hidradenitis suppurativa.
  • Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)
    Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial

Retrieved on: 
星期四, 三月 7, 2024
Queen Square, Doctor of Philosophy, Aes, TREM, CXCL8, CXCL1, Blood, IL-6, Cerebrospinal fluid, Inflammation, Neuroinflammation, NLRP3, Șaeș, Fibrinogen, Volunteering, Risk, Human, Biomarker, AFL, CRP, Patient, Pharmacokinetics, Disease, DSM-IV codes, MRCP, MBBS, Brain, CCL2, Mouse, Face, Pharmaceutical industry

IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.

Key Points: 
  • IL-1β, IL-6, CCL2, CXCL1 and CXCL8) over 28 days compared to baseline to levels approximating those of healthy elderly controls, demonstrating reversal of NLRP3-mediated neuroinflammation.
  • In addition, reductions in neurodegenerative markers were also observed following oral dosing of NT-0796, including NfL and soluble TREM (sTREM2).
  • The correlation between Parkinson’s disease and neuroinflammation is well-documented, with alpha-synuclein fibrils triggering microglial NLRP3 activation, leading to neuroinflammation and subsequent neurodegeneration.
  • This is the inaugural demonstration of an NLRP3 inhibitor’s potential to not only address Parkinson’s disease but also offer a broader impact on neurodegenerative diseases.